Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like A*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000077 AbbVie 03/31/2020 00074634702 HUMIRA (adalimumab) 10mg/0.2mL, 2 Syringe 01/01/2020 382.88 5556.97 06/03/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074937402 HUMIRA (adalimumab) 20mg/0.4mL, 2 Syringe 01/01/2020 382.88 5556.97 06/03/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074379906 HUMIRA (adalimumab) 40MG/0.8ML , 6 Syringe 01/01/2020 1148.65 16670.97 06/03/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074433902 HUMIRA (adalimumab) 40mg/0.8mL, 2 Pen 01/01/2020 382.88 5556.97 06/03/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074379902 HUMIRA (adalimumab) 40mg/0.8mL, 2 Syringe 01/01/2020 382.88 5556.97 06/03/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074379903 HUMIRA (adalimumab) 40MG/0.8ML, 3 Syringe 01/01/2020 574.32 8335.48 06/03/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074433907 HUMIRA (adalimumab) 40mg/0.8mL, 4 Pen 01/01/2020 765.76 11113.96 06/03/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074433906 HUMIRA (adalimumab) 40mg/0.8mL, 6 Pen 01/01/2020 1148.65 16670.97 06/03/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074105305 LUPANETA (leuprolide acetate for depot suspension and norethindrone acetate) 11.25mg, 1 Kit 01/01/2020 288.69 4189.84 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074105205 LUPANETA (leuprolide acetate for depot suspension and norethindrone acetate) 3.75mg, 1 Kit 01/01/2020 96.23 1396.60 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074366303 LUPRON DEPOT (leuprolide acetate) 11.25mg, 1 Kit 01/01/2020 288.69 4189.84 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074334603 LUPRON DEPOT (leuprolide acetate) 22.5mg, 1 Kit 01/01/2020 344.01 4992.79 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074364103 LUPRON DEPOT (leuprolide acetate) 3.75mg, 1 Kit 01/01/2020 96.23 1396.60 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074368303 LUPRON DEPOT (leuprolide acetate) 30mg, 1 Kit 01/01/2020 458.68 6657.06 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074347303 LUPRON DEPOT (leuprolide acetate) 45mg, 1 Kit 01/01/2020 688.03 9985.73 02/05/2031 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074364203 LUPRON DEPOT (leuprolide acetate) 7.5mg, 1 Kit 01/01/2020 114.67 1664.27 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074377903 LUPRON DEPOT PED (leuprolide acetate) 11.25mg, 1 Kit (3 mo) 01/01/2020 630.49 9150.69 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074228203 LUPRON DEPOT PED (leuprolide acetate) 11.25mg, PDS Kit 01/01/2020 210.16 3050.22 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074244003 LUPRON DEPOT PED (leuprolide acetate) 15mg, 1 Kit 01/01/2020 231.47 3359.51 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074969403 LUPRON DEPOT PED (leuprolide acetate) 30mg, 1 Kit 01/01/2020 694.43 10078.56 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074210803 LUPRON DEPOT PED (leuprolide acetate) 7.5mg, 1 Kit 01/01/2020 115.76 1680.11 None Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074057611 VENCLEXTA (venetoclax) 100mg, 1 Tablet 01/01/2020 4.88 102.44 09/06/2033 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074057622 VENCLEXTA (venetoclax) 100mg, 120 Tablet 01/01/2020 585.40 12293.47 09/06/2033 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074056114 VENCLEXTA (venetoclax) 10mg, 14 2 TABLETS X 7 01/01/2020 6.83 143.42 09/06/2033 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074056111 VENCLEXTA (venetoclax) 10mg, 2 Tablet 01/01/2020 0.98 20.49 09/06/2033 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074057928 VENCLEXTA (venetoclax) 10MG, 50MG, 100MG , 1 4X7 DAY WALLET 01/01/2020 126.35 2653.34 09/06/2033 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074056611 VENCLEXTA (venetoclax) 50mg, 1 Tablet 01/01/2020 2.44 51.22 09/06/2033 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000077 AbbVie 03/31/2020 00074056607 VENCLEXTA (venetoclax) 50mg, 7 1 TABLET X 7 01/01/2020 17.07 358.56 09/06/2033 Single Source Drug None 1 AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None NA None None None None None None None None None None None Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000018 ACADIA Pharmaceuticals Inc. 06/30/2020 63090034030 NUPLAZID Oral Capsule 34 MG 30 06/29/2020 297.00 3638.00 08/27/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions:. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000018 ACADIA Pharmaceuticals Inc. 06/30/2020 63090010030 NUPLAZID Oral Tablet 10 MG 30 06/29/2020 297.00 3638.00 08/27/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000278 Acella Pharamceuticals, LLC 03/31/2020 42192071401 Ciclopirox Treatment External Kit,8%, 34.6 ML, Cream 01/03/2020 46.03 316.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=455, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=457 Columns 14 through 22 were left blank because this product was not acquired from another manufacturer within the last five years.
Rx0000278 Acella Pharamceuticals, LLC 09/30/2020 42192071401 Ciclopirox Treatment External  Kit, 8%, 34.6 ML, Cream 08/03/2020 14.22 330.22 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=456 Columns 14 thru 22 were not completed as the product was not acquired within the last 5 years.
Rx0000278 Acella Pharamceuticals, LLC 12/31/2020 42192011270 Salicylic Acid External Foam, 6 %, Size 70GM, Unit-of-Use, Can, 10/05/2020 6.97 161.76 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=458 Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years.
Rx0000278 Acella Pharamceuticals, LLC 12/31/2020 42192014301 Sulfacetamide Sodium-Sulfur (SSS) 10-5 External Foam 10-5 %, Size 100GM, Unit-of-Use, Can 10/05/2020 16.90 392.54 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=459 Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years.
Rx0000278 Acella Pharamceuticals, LLC 12/31/2020 42192014360 Sulfacetamide Sodium-Sulfur (SSS) 10-5 External Foam 10-5 %, Size 60GM, Unit-of-Use, Can 10/05/2020 12.68 294.40 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=460 Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years.
Rx0000157 Acrotech Biopharma LLC 06/30/2020 72893000201 BELEODAQ (belinostat) Injection 500 mg 04/01/2020 30.01 2031.00 10/27/2027 Single Source Drug None 1 None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 1885.30 None 2014 1500.00 None None
Rx0000157 Acrotech Biopharma LLC 03/31/2020 72893000201 BELEODAQ (belinostat) Injection 500 mg, Single dose vial 01/01/2020 29.57 2000.99 10/27/2027 Single Source Drug None 1 None 1 None 1 03/01/2019 Sprectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 1885.30 None 2014 1500.00 https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=416 Acrotech Biopharma is updating the NDC number for Beleodaq to replace Spectrum Pharmaceutical’s labeler code (68152) with Acrotech Biopharma’s (72893) labeler code. Please see the below: • New NDC (Acrotech): 72893-0002-01 • Old NDC (Spectrum): 68152-0109-00
Rx0000157 Acrotech Biopharma LLC 03/31/2020 48818000101 FOLOTYN (pralatrexate) Injection 20 mg, 20mg/mL, 1mL vial 01/01/2020 57.14 5770.87 05/31/2025 Single Source Drug None 1 None 1 None 1 03/01/2019 Sprectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 5442.69 None 2009 3125.00 None None
Rx0000157 Acrotech Biopharma LLC 06/30/2020 48818000101 FOLOTYN (pralatrexate) Injection 20 mg, 20mg/mL, 1mL vial 04/01/2020 109.65 5880.52 05/31/2025 Single Source Drug None 1 None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 5442.69 None 2009 3125.00 None None
Rx0000157 Acrotech Biopharma LLC 03/31/2020 48818000102 FOLOTYN (pralatrexate) Injection 40 mg,20mg/mL, 2mL vial 01/01/2020 114.27 11541.74 05/31/2025 Single Source Drug None 1 None 1 None 1 03/01/2019 Sprectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 10885.38 None 2009 6250.00 None None
Rx0000157 Acrotech Biopharma LLC 06/30/2020 48818000102 FOLOTYN (pralatrexate) Injection 40 mg,20mg/mL, 2mL vial 04/01/2020 219.29 11761.04 05/31/2025 Single Source Drug None 1 None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 10885.38 None 2009 6250.00 None None
Rx0000157 Acrotech Biopharma LLC 03/31/2020 68152011201 KHAPZORY (levoleucovorin) injection 175, Single dose vial mg 01/01/2020 7.00 707.00 None Single Source Drug None 1 None 1 None 1 03/01/2019 Sprectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 700.00 None 2019 700.00 None None
Rx0000157 Acrotech Biopharma LLC 03/31/2020 68152011401 KHAPZORY (levoleucovorin) injection 300 mg, Single dose vial 01/01/2020 12.00 1212.00 None Single Source Drug None 1 None 1 None 1 03/01/2019 Sprectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 1200.00 None 2019 1200.00 None None
Rx0000157 Acrotech Biopharma LLC 06/30/2020 72893000803 MARQIBO (vincristine sulfate) Injection 5 mg, 5mg/31mL, Single-Dose Vial 04/01/2020 587.90 15662.36 09/25/2020 Single Source Drug None 1 None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 14294.21 None 2013 9750.00 https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=440 There was an NDC change to move from the Sprectrum Pharmaceuticals NDC to Acrotech Biopharma's NDC. Please see attached Notification dated May 20, 2020
Rx0000157 Acrotech Biopharma LLC 06/30/2020 72893000704 ZEVALIN (Ibritumomab Tiuxetan), Injection 3.2 mg, 3.2mg/2mL, Single-Dose 2mL Vial 04/01/2020 821.32 55575.64 12/31/2020 Single Source Drug None 1 None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 16000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 49949.21 None 2002 40068.00 https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=441 There was an NDC change to move from the Sprectrum Pharmaceuticals NDC to Acrotech Biopharma's NDC. Please see attached Notification dated May 19, 2020
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2020 76431011001 JUXTAPID 10 MG CAPS, bottle of 28 capsules 01/01/2020 4042.68 44713.53 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2020 76431012001 JUXTAPID 20 MG CAPS, bottle of 28 capsules 01/01/2020 4042.68 44713.53 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2020 76431013001 JUXTAPID 30 MG CAPS, bottle of 28 capsules 01/01/2020 4042.68 44713.53 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2020 76431014001 JUXTAPID 40 MG CAPS, bottle of 28 capsules 01/01/2020 4042.68 44713.53 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2020 76431010501 JUXTAPID 5 MG CAPS - bottle of 28 01/01/2020 4042.68 44713.53 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2020 76431016001 JUXTAPID 60 MG CAPS, bottle of 28 capsules 01/01/2020 4042.68 44713.53 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2020 76431021001 MYALEPT 11.3MG VIAL 01/01/2020 460.50 5093.32 None Single Source Drug None 1 None 1 None 1 01/12/2015 Astra Zeneca 325000000 None None 3493.00 3493.00 2014 3493.00 None The product was introduced to the market before it was acquired by Aegerion Pharmaceuticals which was later acquired by Amryt in 2019. The information provided in this report is the only information available to Amryt. Amryt has no knowledge of the WAC at introduction. Therefore the WAC Aegerion set after acquisition was used - 3493.00 as shown in MediSpan.
Rx0000085 Akorn Inc 03/31/2020 17478050305 Dehydrated Alcohol 0.98mL/mL, 5mL, 10 01/24/2020 3172.57 4467.57 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Columns 14:22- Acquisition information not applicable as this is an Akorn developed product. Column 6- No known patents. This NDC is an unapproved product and does not have an FDA approved application.
Rx0000085 Akorn Inc 09/30/2020 17478071130 Lidocaine Hydrochloride Jelly 2%, 30mL 08/17/2020 30.56 106.96 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Columns 14:22- Acquisition information not applicable as this is an Akorn developed product.
Rx0000039 Alkermes, Inc 06/30/2020 65757040403 ARISTADA 1064 mg/3.9mL extended-release injectable suspension, 1 pre-filled syringe 04/03/2020 187.42 3311.21 03/19/2035 Single Source Drug None 1 This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need.  We strive  to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Aristada was developed in-house
Rx0000039 Alkermes, Inc 06/30/2020 65757040103 ARISTADA 441 mg/ 1.6mL extended-release injectable suspension, 1 pre-filled syringe 04/03/2020 77.68 1372.41 03/19/2035 Single Source Drug None 1 This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need.  We strive  to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Aristada was developed in-house
Rx0000039 Alkermes, Inc 06/30/2020 65757040203 ARISTADA 662 mg/2.4mL extended-release injectable suspension, 1 pre-filled syringe 04/03/2020 116.61 2060.17 03/19/2035 Single Source Drug None 1 This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need.  We strive  to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Aristada was developed in-house
Rx0000039 Alkermes, Inc 06/30/2020 65757040303 ARISTADA 882 mg/3.2mL extended-release injectable suspension, 1 pre-filled syringe 04/03/2020 155.36 2744.82 03/19/2035 Single Source Drug None 1 This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need.  We strive  to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Aristada was developed in-house
Rx0000020 Allergan 03/31/2020 00023932110 ALPHAGAN P-0.1 %-10-CAPSULE,DELAYED RELEASE 01/03/2020 15.99 335.77 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023932115 ALPHAGAN P-0.1 %-15-CAPSULE,DELAYED RELEASE 01/03/2020 23.99 503.73 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023932105 ALPHAGAN P-0.1 %-5-CAPSULE,DELAYED RELEASE 01/03/2020 8.00 167.96 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023917710 ALPHAGAN P-0.15 %-10-CAPSULE,DELAYED RELEASE 01/03/2020 17.05 358.04 01/28/2022 Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023917715 ALPHAGAN P-0.15 %-15-CAPSULE,DELAYED RELEASE 01/03/2020 25.58 537.11 01/28/2022 Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023917705 ALPHAGAN P-0.15 %-5-CAPSULE,DELAYED RELEASE 01/03/2020 8.53 179.07 01/28/2022 Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456046101 ARMOUR THYROID-120 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 7.68 161.30 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456045701 ARMOUR THYROID-15 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 3.21 67.45 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456045801 ARMOUR THYROID-30 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 3.77 79.19 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456045901 ARMOUR THYROID-60 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 4.19 87.98 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456046001 ARMOUR THYROID-90 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 6.56 137.83 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980002210 BLEPHAMIDE-10 %-0.2 %-10-CAPSULE,DELAYED RELEASE 01/03/2020 14.55 305.53 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980002205 BLEPHAMIDE-10 %-0.2 %-5-CAPSULE,DELAYED RELEASE 01/03/2020 7.27 152.76 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456141030 BYSTOLIC-10 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 7.16 150.40 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456141090 BYSTOLIC-10 mg-90-CAPSULE,DELAYED RELEASE 01/03/2020 21.49 451.20 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456140263 BYSTOLIC-2.5 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 24.33 510.86 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456140230 BYSTOLIC-2.5 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 7.16 150.40 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456142030 BYSTOLIC-20 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 7.16 150.40 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456142090 BYSTOLIC-20 mg-90-CAPSULE,DELAYED RELEASE 01/03/2020 21.49 451.20 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456140563 BYSTOLIC-5 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 24.33 510.86 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456140530 BYSTOLIC-5 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 7.16 150.40 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456140590 BYSTOLIC-5 mg-90-CAPSULE,DELAYED RELEASE 01/03/2020 21.49 451.20 12/17/2021 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 58914017014 CARAFATE-1 gram/10 mL-420-CAPSULE,DELAYED RELEASE 01/03/2020 10.46 219.74 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 58914017110 CARAFATE-1 gram-100-CAPSULE,DELAYED RELEASE 01/03/2020 19.43 407.94 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023921110 COMBIGAN-0.2 %-0.5 %-10-CAPSULE,DELAYED RELEASE 01/03/2020 17.63 370.31 01/19/2023 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023921115 COMBIGAN-0.2 %-0.5 %-15-CAPSULE,DELAYED RELEASE 01/03/2020 26.45 555.43 01/19/2023 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023921105 COMBIGAN-0.2 %-0.5 %-5-CAPSULE,DELAYED RELEASE 01/03/2020 8.82 185.15 01/19/2023 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456221230 FETZIMA-120 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 19.64 412.44 05/23/2032 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456220228 FETZIMA-20 mg (2)-40 mg (26)-28-CAPSULE,DELAYED RELEASE 01/03/2020 18.33 384.95 05/23/2032 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456222030 FETZIMA-20 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 19.64 412.44 05/23/2032 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456224030 FETZIMA-40 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 19.64 412.44 05/23/2032 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456228030 FETZIMA-80 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 19.64 412.44 05/23/2032 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980022810 FML FORTE-0.25 %-10-CAPSULE,DELAYED RELEASE 01/03/2020 15.28 320.81 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980022805 FML FORTE-0.25 %-5-CAPSULE,DELAYED RELEASE 01/03/2020 7.64 160.40 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980021110 FML-0.1 %-10-CAPSULE,DELAYED RELEASE 01/03/2020 15.28 320.81 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980021105 FML-0.1 %-5-CAPSULE,DELAYED RELEASE 01/03/2020 7.64 160.40 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456201001 LEXAPRO-10 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 57.37 1204.72 02/12/2023 Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456202001 LEXAPRO-20 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 59.86 1257.13 02/12/2023 Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456200501 LEXAPRO-5 mg-100-CAPSULE,DELAYED RELEASE 01/03/2020 54.87 1152.25 02/12/2023 Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456120130 LINZESS-145 mcg-30-CAPSULE,DELAYED RELEASE 01/03/2020 21.19 445.02 08/16/2033 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456120230 LINZESS-290 mcg-30-CAPSULE,DELAYED RELEASE 01/03/2020 21.19 445.02 08/16/2033 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456120330 LINZESS-72 mcg-30-CAPSULE,DELAYED RELEASE 01/03/2020 21.19 445.02 08/16/2033 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00430042014 LO LOESTRIN FE-1 mg-10 mcg (24)/10 mcg (2)/75 mg (2)-28-CAPSULE,DELAYED RELEASE 01/03/2020 35.15 738.75 02/02/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023320503 LUMIGAN-0.01 %-2.5-DROPS 01/03/2020 9.85 206.82 06/13/2027 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023320505 LUMIGAN-0.01 %-5-DROPS 01/03/2020 19.69 413.47 06/13/2027 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023320508 LUMIGAN-0.01 %-7.5-DROPS 01/03/2020 29.53 620.17 06/13/2027 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456430001 MONUROL-3 gram-1-CAPSULE,DELAYED RELEASE 01/03/2020 4.35 91.27 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456121430 NAMZARIC-14 mg-10 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 23.13 485.79 12/05/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456122130 NAMZARIC-21 mg-10 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 23.13 485.79 12/05/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456122830 NAMZARIC-28 mg-10 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 23.13 485.79 12/05/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456122929 NAMZARIC-7 mg-10 mg (7)/14 mg-10 mg (7)/21 mg-10 mg(7)/28 mg-10 mg(7)-28-CAPSULE,DELAYED RELEASE 01/03/2020 21.59 453.40 12/05/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456120730 NAMZARIC-7 mg-10 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 23.13 485.79 12/05/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980018010 PRED FORTE-1 %-10-CAPSULE,DELAYED RELEASE 01/03/2020 14.55 305.53 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980018015 PRED FORTE-1 %-15-CAPSULE,DELAYED RELEASE 01/03/2020 21.82 458.29 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980018005 PRED FORTE-1 %-5-CAPSULE,DELAYED RELEASE 01/03/2020 7.27 152.76 None Innovator Multiple Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980017410 PRED MILD-0.12 %-10-CAPSULE,DELAYED RELEASE 01/03/2020 14.55 305.53 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 11980017405 PRED MILD-0.12 %-5-CAPSULE,DELAYED RELEASE 01/03/2020 7.27 152.76 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023006604 PRED-G-0.3 %-0.6 %-3.5-OINTMENT (GRAM) 01/03/2020 7.27 152.76 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023010605 PRED-G-0.3 %-1 %-5-SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML) 01/03/2020 7.27 152.76 None Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023530105 RESTASIS MULTIDOSE-0.05 %-5.5-DROPS 01/03/2020 27.89 585.61 05/11/2034 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023916330 RESTASIS-0.05 %-30-CAPSULE,DELAYED RELEASE 01/03/2020 13.94 292.79 08/27/2024 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023916360 RESTASIS-0.05 %-60-CAPSULE,DELAYED RELEASE 01/03/2020 27.89 585.61 08/27/2024 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456151060 SAVELLA-100 mg-60-CAPSULE,DELAYED RELEASE 01/03/2020 19.10 401.03 09/19/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456150055 SAVELLA-12.5 mg (5)-25 mg (8)-50 mg (42)-55-CAPSULE,DELAYED RELEASE 01/03/2020 17.51 367.61 09/19/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456151260 SAVELLA-12.5 mg-60-CAPSULE,DELAYED RELEASE 01/03/2020 19.10 401.03 09/19/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456152560 SAVELLA-25 mg-60-CAPSULE,DELAYED RELEASE 01/03/2020 19.10 401.03 09/19/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456155060 SAVELLA-50 mg-60-CAPSULE,DELAYED RELEASE 01/03/2020 19.10 401.03 09/19/2029 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023586228 TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE PACK OF 1 01/03/2020 9.35 196.30 03/29/2020 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023586230 TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE PACK OF 5 01/03/2020 46.74 981.48 03/29/2020 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456040001 TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE PACK OF 1 01/03/2020 9.61 201.73 02/10/2031 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456040010 TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE PACK OF 10 01/03/2020 96.06 2017.27 02/10/2031 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456060001 TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE PACK OF 1 01/03/2020 9.61 201.73 02/10/2031 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456060010 TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE PACK OF 10 01/03/2020 96.06 2017.27 02/10/2031 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 61874010060 VIBERZI-100 mg-60-CAPSULE,DELAYED RELEASE 01/03/2020 62.73 1317.39 03/14/2033 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 61874007560 VIBERZI-75 mg-60-CAPSULE,DELAYED RELEASE 01/03/2020 62.73 1317.39 03/14/2033 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456110130 VIIBRYD-10 mg (7)-20 mg (23)-30-CAPSULE,DELAYED RELEASE 01/03/2020 13.61 285.85 12/05/2022 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456111030 VIIBRYD-10 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 13.61 285.85 12/05/2022 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456112030 VIIBRYD-20 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 13.61 285.85 12/05/2022 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00456114030 VIIBRYD-40 mg-30-CAPSULE,DELAYED RELEASE 01/03/2020 13.61 285.85 12/05/2022 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023611001 ZENPEP-10,000 unit-32,000 unit-42,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 16.75 351.77 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 42865030602 ZENPEP-10,000 unit-34,000 unit-55,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 16.75 351.77 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023611101 ZENPEP-15,000 unit-47,000 unit-63,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 24.19 508.06 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023611201 ZENPEP-20,000 unit-63,000 unit-84,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 32.86 690.13 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 42865030302 ZENPEP-20,000 unit-68,000 unit-109,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 32.86 690.13 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023611601 ZENPEP-25,000 unit-79,000 unit-105,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 40.67 854.01 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 42865030502 ZENPEP-25,000 unit-85,000 unit-136,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 40.67 854.01 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023611301 ZENPEP-3,000 unit-10,000 unit-14,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 8.88 186.51 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 42865030402 ZENPEP-3,000 unit-10,000 unit-16,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 8.88 186.51 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023611401 ZENPEP-40,000 unit-126,000 unit-168,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 64.86 1362.01 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 42865030702 ZENPEP-40,000 unit-136,000 unit-218,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 64.86 1362.01 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 00023611501 ZENPEP-5,000 unit-17,000 unit-24,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 8.47 177.95 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000020 Allergan 03/31/2020 42865030002 ZENPEP-5,000 unit-17,000 unit-27,000 unit-100-CAPSULE,DELAYED RELEASE 01/03/2020 8.47 177.95 02/20/2028 Single Source Drug None 1 AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. None None 1 None None None None None None None None None None None
Rx0000201 Almirall LLC 03/31/2020 16110050201 Acticlate 150mg 60 tablet 01/02/2020 102.33 2204.83 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None None None None None None None None None None None None
Rx0000201 Almirall LLC 03/31/2020 16110050101 Acticlate 75mg 60 tablet 01/02/2020 102.33 2204.83 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None None None None None None None None None None None None
Rx0000201 Almirall LLC 03/31/2020 00023367060 Aczone 5% 60 g 01/02/2020 52.24 687.42 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 593.63 542.13 2008 343.48 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023367090 Aczone 5% 90g 01/02/2020 68.52 901.68 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 778.65 711.10 2008 516.21 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023520660 Aczone 7.5% 60g 01/02/2020 52.24 687.42 11/18/2033 Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None Indication extended to 9 years; post marketing commitment completed None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 593.63 542.13 2016 495.10 None Year of introduction from CMS Medicaid rebate database
Rx0000201 Almirall LLC 03/31/2020 00023520690 Aczone 7.5% 90g 01/02/2020 68.52 901.68 11/18/2033 Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None Indication extended to 9 years; post marketing commitment completed None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 778.65 711.10 2016 649.41 None Year of introduction from CMS Medicaid rebate database
Rx0000201 Almirall LLC 03/31/2020 16110051815 Altabax 1% ointment 15g 01/02/2020 14.73 315.03 02/14/2027 Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 11/15/2015 GlaxoSmithKline None 1 None 151.64 128.83 2007 217.00 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 16110051830 Altabax 1% ointment 30g 01/02/2020 28.79 604.67 02/14/2027 Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 11/15/2015 GlaxoSmithKline None 1 None 288.82 245.38 2007 415.00 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023869450 Azelex 50g 01/02/2020 32.52 682.92 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 607.85 555.11 1995 308.69 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 16110002660 Cordan 0.05% Ointment 60g 01/02/2020 37.64 738.80 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None None None None None None None None None None None None
Rx0000201 Almirall LLC 03/31/2020 16110003512 Cordran 0.05% Cream 120g 01/02/2020 62.37 1224.01 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None None None None None None None None None None None None
Rx0000201 Almirall LLC 03/31/2020 16110005212 Cordran 0.05% Lotion 120ml 01/02/2020 62.37 1224.01 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None None None None None None None None None None None None
Rx0000201 Almirall LLC 03/31/2020 00023587080 Cordran Tape 4 ug/cm2, 1500cm2 01/02/2020 34.02 714.40 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 635.87 580.70 2016 580.70 None Year of introduction from CMS Medicaid rebate database
Rx0000201 Almirall LLC 03/31/2020 16110081230 Fluoroplex 1% cream 30g 01/02/2020 45.90 900.92 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None None None None None None None None None None None None
Rx0000201 Almirall LLC 03/31/2020 00023915530 Tazorac Cream .05% 30g 01/02/2020 19.93 418.46 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 372.46 340.15 2000 221.55 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023915560 Tazorac Cream .05% 60g 01/02/2020 39.85 836.76 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 744.78 680.16 2000 443.01 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023915630 Tazorac Cream 0.1% 30g 01/02/2020 21.17 444.56 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 395.69 361.36 2000 235.36 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023915660 Tazorac Cream 0.1% 60g 01/02/2020 42.33 888.98 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 791.26 722.61 2000 784.49 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023004210 Tazorac Gel .01% 100g 01/02/2020 70.56 1481.75 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 1318.87 1204.45 1997 784.49 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023004203 Tazorac Gel .01% 30g 01/02/2020 21.17 444.56 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 395.69 361.36 1997 235.36 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023833510 Tazorac Gel .05% 100g 01/02/2020 66.41 1394.53 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 1241.23 1133.54 1997 738.30 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 00023833503 Tazorac Gel .05% 30g 01/02/2020 19.93 418.46 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 09/21/2018 Allergan None None Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. 372.46 340.15 1997 217.00 None The company does not have access to launch WACs prior to 2013 for acquired products
Rx0000201 Almirall LLC 03/31/2020 16110007130 Veltin 1.2%/0.025% gel 30g 01/02/2020 22.04 462.74 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 11/15/2015 GlaxoSmithKline None 1 None 243.07 220.97 2010 148.00 None Year of introduction from CMS Medicaid rebate database
Rx0000201 Almirall LLC 03/31/2020 16110007160 Veltin 1.2%/0.025% gel 60g 01/02/2020 41.49 871.24 None Single Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None 11/15/2015 GlaxoSmithKline None 1 None 456.61 415.10 2010 278.00 None Year of introduction from CMS Medicaid rebate database
Rx0000201 Almirall LLC 03/31/2020 16110011100 Verdeso 0.05% foam 100g 01/02/2020 50.57 992.41 08/13/2027 Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None None None None None None None None None None None None
Rx0000201 Almirall LLC 03/31/2020 16110008045 Xolegel 2% gel 45g 01/02/2020 40.06 786.28 None Innovator Multiple Source Drug None 1 When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None N/A None None None None None None None None None None None None
Rx0000037 AMAG Pharmaceuticals, Inc. 03/31/2020 59338077510 ferumoxytol 510MG/17 mL Feraheme (Ferumoxytol Injection) 510mg/17 mL CTN/10 01/01/2020 412.10 10714.20 06/30/2023 Single Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 12/31/2020 59338077501 ferumoxytol 510MG/17 mL Feraheme 510mg Each 10/01/2020 42.86 1114.28 06/30/2023 Single Source Drug None 1 Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_ As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_ The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_ Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_ In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_ We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_ None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 12/31/2020 59338077510 ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10 10/01/2020 428.60 11142.80 06/30/2023 Single Source Drug None 1 Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_ As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_ The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_ Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_ In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_ We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_ None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 03/31/2020 59338077501 ferumoxytol 510MG/17 mL Feraheme (Ferumoxytol Injection) 510mg Each 01/01/2020 41.21 1071.42 06/30/2023 Single Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 03/31/2020 64011060128 Intrarosa (prasterone) 6.5mg vaginal insert Package of 28 01/01/2020 10.30 212.30 03/19/2031 Single Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None 02/14/2017 US commercial rights licensed from Endoceutics 50000000 None At closing, AMAG will pay Endoceutics $50 million of total upfront consideration and issue Endoceutics 600,000 unregistered shares of AMAG common stock. In addition, AMAG will pay Endoceutics up to $10 million upon delivery of adequate launch quantities of Intrarosa and $10 million upon the first anniversary of the effective date of the agreement. Endoceutics will be entitled to certain sales milestone payments, including a first sales milestone payment of $15 million, which would be triggered when Intrarosa annual net U.S. sales exceed $150 million, and a second milestone payment of $30 million, which would be triggered when annual net U.S. sales exceed $300 million. Should annual net U.S. sales exceed $500 million, there are additional sales milestone payments of up to $850 million, which would be triggered at various sales thresholds. AMAG will also pay Endoceutics tiered royalties as a percent of Intrarosa net sales. 1.00 0.00 2017 175.00 None Product acquired pre-launch
Rx0000050 Amarin Pharma, Inc. 12/31/2020 52937000120 Vascepa(Icosapent ethyl) 120 1g 12/29/2020 13.24 344.22 06/28/2033 Single Source Drug 3158613 None Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study. • The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold. • On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6 1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22. 2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019. Accessed March 28, 2019. 3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455. 4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687. 5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014. 6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019. 7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. None On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA • as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and o Established cardiovascular disease, or o Diabetes and two or more additional risk factors for cardiovascular disease The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy. Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5 1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22. 2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019. Accessed March 28, 2019. 3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455. 4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687. 5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014. 6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019. 7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. None None None None None None None None None None None None
Rx0000050 Amarin Pharma, Inc. 12/31/2020 52937000340 Vascepa(Icosapent ethyl) 240 500mg 12/29/2020 15.49 402.73 06/28/2033 Single Source Drug 3485 None Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study. • The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold. • On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6 1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22. 2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019. Accessed March 28, 2019. 3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455. 4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687. 5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014. 6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019. 7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. None On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA • as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and o Established cardiovascular disease, or o Diabetes and two or more additional risk factors for cardiovascular disease The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy. Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5 1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22. 2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019. Accessed March 28, 2019. 3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455. 4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687. 5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014. 6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019. 7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. None None None None None None None None None None None None
Rx0000231 American Health Packaging 12/31/2020 60687012125 ACAMPROSATE CALCIUM DR TABLET 333MG 30UD 11/02/2020 17.32 58.97 None Non-innovator Multiple Source Drug 8953 None Market Conditions None No Change Improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2020 60687031425 Azithromycin Tablet 600mg 30UD 09/22/2020 45.79 159.27 None Non-innovator Multiple Source Drug 1818 None Market Conditions None No Change Improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2020 68001039700 FAMOTIDINE TAB 20MG 100 12/01/2020 7.23 14.00 None Non-innovator Multiple Source Drug 107510 None Market Conditions None No Change Improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2020 68001039708 FAMOTIDINE TAB 20MG 1000 12/01/2020 78.28 140.00 None Non-innovator Multiple Source Drug 20150 None Market Conditions None No Change Improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2020 68001039800 FAMOTIDINE TAB 40MG 100 12/01/2020 15.77 28.00 None Non-innovator Multiple Source Drug 48412 None Market Conditions None No Change Improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2020 68001039803 FAMOTIDINE TAB 40MG 500 12/01/2020 40.02 140.00 None Non-innovator Multiple Source Drug 7288 None Market Conditions None No Change Improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2020 68084082321 Methylphenidate HCl Tablet CII 10mg 30UD 01/16/2020 10.23 44.41 None Non-innovator Multiple Source Drug 5487 None Market conditions None No change/improvement in drug product description/Not applicable. None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2020 68084067601 Metoclopramide Tablet 10mg 100UD 07/24/2020 20.00 60.00 None Non-innovator Multiple Source Drug 19755 None Market Conditions None No Change Improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 06/30/2020 60687037401 NABUMETONE TAB 500MG 100UD 04/06/2020 13.19 118.19 None Non-innovator Multiple Source Drug 1278 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2020 60687015625 Phenytoin Chew Tablet 50mg 30UD 02/26/2020 15.59 45.00 None Non-innovator Multiple Source Drug 10773 None Market conditions None No change/improvement in the drug product description None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128 American Regent 09/30/2020 00517065001 Injectafer Intravenous Solution 750 MG/15ML 07/01/2020 33.19 1139.67 02/15/2028 Single Source Drug 696537 None American Regent’s US Standards of Business Conduct (available at https://www.americanregent.com/media/2747/us-sobc-112019.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. None N/A None None None None None None None None None None None Injectafer is not an acquired product. American Regent is the NDA holder of this NDC.
Rx0000128 American Regent 03/31/2020 00517037405 PROVAYBLUE (METHYLENE BLUE) 5 MG/ML, 10 ML AMPULE, PKG. OF 5 03/31/2020 156.82 1189.87 None Innovator Multiple Source Drug 67316967 None American Regent’s US Standards of Business Conduct (available at http://ari.americanregent.com/Files/Compliance/US_Standards_of_Business_Conduct_21NOV2019.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. None No improvement None None None None None None None None None None None ProvayBlue is not an acquired product. The partner from whom we license the drug, (which is not affiliated with American Regent) is the NDA holder of this NDC.
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896066930 Emverm Chewable Tablet 100 MG 02/25/2020 41.92 465.31 None Single Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 405.53 None 2018 405.53 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 60846030115 Nizatidine Oral Solution 15mg/mL 480 Bottle 01/20/2020 50.63 557.41 None Single Source Drug 0 1 None 1 None 1 07/10/1905 Gemini None 1 None 419.59 None 2018 419.59 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069701 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 100 tablets 07/06/2020 44.18 486.41 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 381.56 381.56 2019 381.56 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069713 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 60 tablets 07/06/2020 26.51 291.85 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 228.94 228.94 2019 228.94 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069801 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 100 tablets 07/06/2020 61.26 674.52 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 529.13 529.13 2019 529.13 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069813 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 60 tablets 07/06/2020 36.76 404.72 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 317.48 317.48 2019 317.48 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069901 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 100 tablets 07/06/2020 78.36 862.70 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 676.74 676.74 2019 676.74 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069913 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 60 tablets 07/06/2020 47.01 517.62 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 406.05 406.05 2019 406.05 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896070001 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 100 tablets 07/06/2020 112.78 1241.72 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 974.06 974.06 2019 974.06 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896070013 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 60 tablets 07/06/2020 67.67 745.04 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 584.44 584.44 2019 584.44 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896070101 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 100 tablets 07/06/2020 147.21 1620.75 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 1271.39 1271.39 2019 1271.39 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896070113 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 60 tablets 07/06/2020 88.32 972.45 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 762.84 762.84 2019 762.84 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069501 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 100 tablets 07/06/2020 23.01 253.31 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 198.71 198.71 2019 198.71 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069513 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 60 tablets 07/06/2020 13.80 151.98 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 119.22 119.22 2019 119.22 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069601 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 100 tablets 07/06/2020 33.59 369.84 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 290.12 290.12 2019 290.12 None None
Rx0000122 Amneal Pharmaceuticals 09/30/2020 64896069613 oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 60 tablets 07/06/2020 20.15 221.90 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 174.07 174.07 2019 174.07 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896066101 Rytary 23.75mg/95mg ER Cap 100ct 02/25/2020 14.42 334.98 None Single Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 291.68 None 2018 291.68 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896066201 Rytary 36.25mg/145mg ER Cap 100ct 02/25/2020 14.42 334.98 None Single Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 291.68 None 2018 291.68 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896066301 Rytary 48.75mg/195mg ER Cap 100ct 02/25/2020 14.42 334.98 None Single Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 291.68 None 2018 291.68 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896066401 Rytary 61.25mg/245mg ER Cap 100ct 02/25/2020 18.13 420.92 None Single Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 366.51 None 2018 366.51 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896067151 Zomig 2.5 mg 6 tab blister 02/25/2020 69.92 776.18 None Innovator Multiple Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 584.75 None 2018 584.75 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896068251 Zomig 2.5 mg Nasal Spray (2x3 packs) 02/25/2020 48.08 533.73 None Single Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 402.09 None 2018 402.09 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896067250 Zomig 5 mg 3 tab blister 02/25/2020 34.96 388.08 None Innovator Multiple Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 292.37 None 2018 292.37 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896068151 Zomig 5 mg Nasal Spray (2x3 packs) 02/25/2020 48.08 533.73 None Single Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 402.09 None 2018 402.09 None None
Rx0000122 Amneal Pharmaceuticals 12/31/2020 64896068251 Zomig Nasal Solution 2.5 MG, Package size of 6 tablets 12/01/2020 52.84 586.57 None Single Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 402.09 402.09 2018 402.09 None None
Rx0000122 Amneal Pharmaceuticals 12/31/2020 64896068151 Zomig Nasal Solution 5 MG, Package size of 6 tablets 12/01/2020 52.84 586.57 None Single Source Drug None 1 None 1 None 1 05/07/2018 IMPAX None 1 This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. 402.09 402.09 2018 402.09 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896069151 Zomig ZMT 2.5 mg 6 tab blister 02/25/2020 69.92 776.18 None Innovator Multiple Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 584.75 None 2018 584.75 None None
Rx0000122 Amneal Pharmaceuticals 03/31/2020 64896069250 Zomig ZMT 5 mg 3 tab blister 02/25/2020 34.96 388.08 None Innovator Multiple Source Drug 0 1 None 1 None 1 07/10/1905 Impax None 1 None 292.37 None 2018 292.37 None None
Rx0000176 ANIP 03/31/2020 62559067030 Arimidex 1mg Tab 30 03/01/2020 129.93 1497.59 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559068030 Casodex 50mg Tab 30 03/01/2020 285.97 3296.13 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559011107 Cortenema 100mg/60mL Enema 7 03/01/2020 33.82 166.85 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559013807 HC 100mg/60mL Enema 7 03/01/2020 30.55 150.00 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559052201 Inderal LA 120mg Cap 100 03/01/2020 646.29 7449.39 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559052301 Inderal LA 160mg Cap 100 03/01/2020 674.68 7776.58 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559052001 Inderal LA 60mg Cap 100 03/01/2020 502.45 5791.35 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559052101 Inderal LA 80mg Cap 100 03/01/2020 586.87 6764.41 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559060130 Inderal XL 120mg Cap 30 03/01/2020 173.84 2003.74 10/04/2021 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559060030 Inderal XL 80mg Cap 30 03/01/2020 173.84 2003.74 10/04/2021 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559059130 InnoPran XL 120mg Cap 30 03/01/2020 173.84 2003.74 10/04/2021 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559059030 InnoPran XL 80mg Cap 30 03/01/2020 173.84 2003.74 10/04/2021 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559028001 Lithobid 300mg Tab 100 03/01/2020 110.57 1274.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559016601 Reglan 10mg Tab 100 03/01/2020 29.54 340.48 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559016501 Reglan 5mg Tab 100 03/01/2020 29.54 340.48 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559031020 Vancocin 125mg Cap 20 03/01/2020 149.44 1722.44 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000176 ANIP 03/31/2020 62559031120 Vancocin 250mg Cap 20 03/01/2020 275.52 3175.78 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines.
Rx0000274 Artesa Labs, LLC 06/30/2020 57893020360 Nicaprin, Dietary Supplement, Tablet, 60 ct. 05/30/2020 54.00 590.00 None Single Source Drug 17838 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000075 Assertio Therapeutics, Inc. 03/31/2020 13913001201 Cambia (diclofenac potassium) 50MG Oral 1 Packet 01/03/2020 7.49 83.11 06/16/2026 Single Source Drug 959886 None None 1 None 1 None None None None None None None None None None This drug was not acquired in the past five years
Rx0000075 Assertio Therapeutics, Inc. 03/31/2020 13913000812 Zipsor (diclofenac potassium) 25MG Oral Capsule 120 Ct Bottle 01/03/2020 141.48 1570.55 02/24/2029 Single Source Drug 2806920 None None 1 None 1 None None None None None None None None None None This drug was not acquired in the past five years
Rx0000015 AstraZeneca 09/30/2020 00186077660 Brilinta 60mg Tablets 60 count bottle 07/01/2020 7.71 393.03 01/27/2036 Single Source Drug 181368340 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 09/30/2020 00186077739 Brilinta 90mg Tablets 100 count box 07/01/2020 12.85 655.04 01/27/2036 Single Source Drug 28772299 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 09/30/2020 00186077760 Brilinta 90mg Tablets 60 count bottle 07/01/2020 7.71 393.03 01/27/2036 Single Source Drug 1182543013 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 09/30/2020 00310654004 Bydureon 2mg Autoinjector 4 Syringes 07/01/2020 14.42 735.18 10/04/2030 Single Source Drug 668761831 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/01/2014 Bristol-Myers Squibb 2700000000 None AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. 407.45 None 2012 323.44 None None
Rx0000015 AstraZeneca 09/30/2020 00310653004 Bydureon 2mg Pen 4 Syringes 07/01/2020 14.42 735.18 03/21/2028 Single Source Drug 815082319 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/01/2014 Bristol-Myers Squibb 2700000000 None AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. 407.45 None 2012 323.44 None None
Rx0000015 AstraZeneca 09/30/2020 00310009530 Daliresp 500mcg Tablets 30 count bottle 07/01/2020 21.67 382.85 03/08/2024 Single Source Drug 214201592 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/04/2015 Forest Laboratories, LLC 280000000 None The Daliresp acquisition was part of a larger acquisition that included other assets, the estimated portion for Daliresp was approximately $280 million. The acquisition was made from Forest Laboratories, LLC which was owned by Actavis PLC at the time of acquisition. 257.88 None 2011 172.50 None None
Rx0000015 AstraZeneca 09/30/2020 00310009590 Daliresp 500mcg Tablets 90 count bottle 07/01/2020 65.01 1148.57 03/08/2024 Single Source Drug 49787415 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/04/2015 Forest Laboratories, LLC 280000000 None The Daliresp acquisition was part of a larger acquisition that included other assets, the estimated portion for Daliresp was approximately $280 million. The acquisition was made from Forest Laboratories, LLC which was owned by Actavis PLC at the time of acquisition. 773.65 None 2012 517.50 None None
Rx0000015 AstraZeneca 03/31/2020 00310621030 Farxiga 10mg Tablets 30 Count Bottle 01/01/2020 14.77 507.18 05/26/2030 Single Source Drug 1438170485 None "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. " None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/01/2014 Bristol-Myers Squibb 2700000000 None AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. 289.20 289.20 2014 289.20 None We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
Rx0000015 AstraZeneca 09/30/2020 00310621030 Farxiga 10mg tablets 30 count bottle 07/01/2020 10.14 517.32 05/26/2030 Single Source Drug 1438170485 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/01/2014 Bristol-Myers Squibb 2700000000 None AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. 289.20 None 2014 289.20 None None
Rx0000015 AstraZeneca 03/31/2020 00310620530 Farxiga 5mg Tablets 30 Count Bottle 01/01/2020 14.77 507.18 05/26/2030 Single Source Drug 590696676 None "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. " None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/01/2014 Bristol-Myers Squibb 2700000000 None AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. 289.20 289.20 2014 289.20 None We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
Rx0000015 AstraZeneca 09/30/2020 00310620530 Farxiga 5mg Tablets 30 count bottle 07/01/2020 10.14 517.32 05/26/2030 Single Source Drug 590696676 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/01/2014 Bristol-Myers Squibb 2700000000 None AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. 289.20 None 2014 289.20 None None
Rx0000015 AstraZeneca 03/31/2020 00310678030 Qtern 5mg-10mg Tablets 30 Count Bottle 01/01/2020 14.77 507.18 12/16/2029 Single Source Drug 10919684 None "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. " None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
Rx0000015 AstraZeneca 09/30/2020 00310678030 Qtern 5mg-10mg Tablets 30 count bottle 07/01/2020 10.14 517.32 12/16/2029 Single Source Drug 10919684 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 09/30/2020 00186037020 Symbicort 160/4.5mcg HFA Aerosol 1 Inhaler 07/01/2020 7.15 364.38 10/07/2029 Innovator Multiple Source Drug None None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 09/30/2020 00186037028 Symbicort 160/4.5mcg HFA Aerosol 1 Inhaler Inst Pack 07/01/2020 4.85 247.60 10/07/2029 Innovator Multiple Source Drug 159106270 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 09/30/2020 00186037220 Symbicort 80/4.5mcg HFA Aerosol 1 Inhaler 07/01/2020 6.25 318.78 10/07/2029 Innovator Multiple Source Drug 1020316295 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 09/30/2020 00186037228 Symbicort 80/4.5mcg HFA Aerosol 1 Inhaler Inst Pack 07/01/2020 4.22 215.24 10/07/2029 Innovator Multiple Source Drug 43272143 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 03/31/2020 00310628030 Xigduo XR 10-1000mg Tablets 30 Count Bottle 01/01/2020 14.77 507.18 11/12/2030 Single Source Drug 128234044 None "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. " None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
Rx0000015 AstraZeneca 09/30/2020 00310628030 Xigduo XR 10-1000mg Tablets 30 count bottle 07/01/2020 10.14 517.32 11/12/2030 Single Source Drug 128234044 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 03/31/2020 00310627030 Xigduo XR 10-500mg Tablets 30 Count Bottle 01/01/2020 14.77 507.18 11/12/2030 Single Source Drug 13548819 None "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. " None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
Rx0000015 AstraZeneca 09/30/2020 00310627030 Xigduo XR 10-500mg Tablets 30 count bottle 07/01/2020 10.14 517.32 11/12/2030 Single Source Drug 13548819 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 03/31/2020 00310626060 Xigduo XR 5-1000mg Tablets 60 Count Bottle 01/01/2020 14.77 507.18 11/12/2030 Single Source Drug 237728896 None "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. " None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
Rx0000015 AstraZeneca 09/30/2020 00310626060 Xigduo XR 5-1000mg Tablets 60 count bottle 07/01/2020 10.14 517.32 11/12/2030 Single Source Drug 237728896 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000015 AstraZeneca 03/31/2020 00310625030 Xigduo XR 5-500mg Tablets 30 Count Bottle 01/01/2020 14.77 507.18 11/12/2030 Single Source Drug 23387060 None "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. " None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
Rx0000015 AstraZeneca 09/30/2020 00310625030 Xigduo XR 5-500mg Tablets 30 count bottle 07/01/2020 10.14 517.32 11/12/2030 Single Source Drug 23387060 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None None
Rx0000265 Atland Pharmaceuticals 06/30/2020 71993030030 Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets (325 mg/ 30 mg/ 16 mg) 04/02/2020 150.00 600.00 None Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None Atland acquired product ANDA 204209 from Larken the rights to market and distribute the NDC under a licensing agreement, the terms of which are not publicly available.
Rx0000058 Avanir Pharmaceuiticals 03/31/2020 64597030160 NUEDEXTA (Dextromethorphan hydrobromide 20mg and quinidine sulfate 10mg capsules); 60 capsules per bottle 01/01/2020 76.40 1250.40 08/13/2026 Single Source Drug None 1 Avanir is committed to making responsible pricing determinations, and in so doing we consider a range of factors. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Avanir are made at the executive level in adherence with all federal and state laws. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None The reason for the blank acquisition-related fields (14-22) is that Neudexta was not acquired.